[카테고리:] 뉴스 (News)

Let’s take a look at the interview article with ‘Korea Biomedical Review’ of 3billion’s CEO Changwon Keum. There are many difficulties in diagnosing rare genetic disorders as well as finding cures. Each patient has an average of 100,000 genetic variants, and it is not easy to determine one pathogenic variant that causes a rare genetic…

3billion has received CAP accreditation on November 15th. CAP accreditation is an evaluation system by the College of American Pathologists, an organization of clinical pathologists in the United States. This accreditation officially signifies that the quality of our rare disease diagnostic services meets global standards. 3billion currently provides services to more than 200 institutions in…

SEOUL, SOUTH KOREA—3billion has announced 3Cnet, a pathogenicity prediction tool based on recurrent neural networks (RNN). 3Cnet boasts a top-1 recall of 14.5%–approximately 2.2 times greater than REVEL’s leading top-1 recall of 6.5%–when used to retrieve pathogenic variants in 111 patient cases diagnosed according to the ACMG guidelines, respectively. 3Cnet’s fundamental approach utilizes protein sequences…